OTC review
This article was originally published in The Tan Sheet
Executive Summary
FDA issues call for data on antidiarrheal ingredient Saccharomyces boulardii 250 mg in capsule form taken one to two times daily, according to a notice slated for publication in the Federal Register Aug. 23. The agency "has reviewed a time and extent application for this condition and determined that it is eligible for consideration in its OTC drug monograph system." The notice adds that either an official or proposed U.S. Pharmacopoeia-National Formulary monograph must be submitted as part of the review because one was not included as part of the TEA...
You may also be interested in...
FDA withdraws monograph bid for diarrhea drug
FDA withdraws its 2004 notice of eligibility and request for information to aid its consideration of adding Saccharomyces boulardii to the antidiarrheal OTC drug product monograph. FDA determined the yeast is best regulated as a biological product, the agency said in an Oct. 27 notice in the Federal Register (1"The Tan Sheet" Aug. 23, 2004, In Brief)
EU: Good News For IVDs And For Future Transparency Of Medtech Compliance
The IVD industry has long been awaiting a further extension of the deadlines for compliance with the IVD Regulation and for the launch date of the Eudamed database to be brought forward.
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.